TABLE 2.

COVID-19 Vaccine Reactogenicity After Dose 1 and Dose 2 Reported During Parent/Guardian Interview for Children With History of Hospitalization for MIS-C or Acute COVID-19

	Multisystem Inflammatory Syndrome in Children		Acute COVID-19
	Dose 1, n (%) (n = 20)*	Dose 2, n (%) (n = 19)†	Dose 1, n (%) (n = 15)‡	Dose 2, n (%) (n = 14)§
Pain at injection site	10 (50)	4 (21)	8 (53)	7 (50)
Redness at injection site	1 (5)	2 (11)	1 (7)	2 (14)
Swelling at injection site	1 (5)	1 (5)	3 (20)	2 (14)
Subjective or objective (≥38 °C) fever	0 (0)	1 (5)	3 (20)	2 (14)
Chills	2 (10)	1 (5)	2 (13)	1 (7)
Fatigue	2 (10)	2 (11)	2 (13)	4 (29)
Headache	3 (15)	2 (11)	2 (13)	2 (14)
Vomiting	0 (0)	0 (0)	1 (7)	0 (0)
Diarrhea	0 (0)	0 (0)	1 (7)	0 (0)
New or worsened muscle pain	4 (20)	2 (11)	1 (7)	1 (7)
New or worsened joint pain	2 (10)	2 (11)	1 (7)	1 (7)
Rash	2 (10)	1 (5)	0 (0)	0 (0)
Other symptom¶	0 (0)	1 (5)	1 (7)	0 (0)
Used fever-reducing or pain medicine for symptoms/side effects	5 (25)	3 (16)	7 (47)	6 (43)
Symptoms/side effects interfered with normal daily activities‖	2 (10)	0 (0)	2 (13)	1 (7)

^*Symptoms after dose 1 had a mean duration of 1.8 (range 1–3) days.

^†Symptoms after dose 2 had a mean duration of 1.8 (range 1–3) days.

^‡Symptoms after dose 1 had a mean duration of 2 (range 1–4) days.

^§Symptoms after dose 2 had a mean duration of 1.9 (range 1–5) days.

^¶One individual with runny nose/nasal congestion and one with epistaxis; interviewees were also asked about chest pain or pressure, and none reported these symptoms.

^‖Among children with MIS-C, symptoms interfered with activities of daily living for 1 day; among children with acute COVID-19, interference duration was 2–3 days.